[go: up one dir, main page]

NO20064676L - Pharmaceutical salts of 3-O- (3'3'-dimethylsuccinyl) betulinic acid - Google Patents

Pharmaceutical salts of 3-O- (3'3'-dimethylsuccinyl) betulinic acid

Info

Publication number
NO20064676L
NO20064676L NO20064676A NO20064676A NO20064676L NO 20064676 L NO20064676 L NO 20064676L NO 20064676 A NO20064676 A NO 20064676A NO 20064676 A NO20064676 A NO 20064676A NO 20064676 L NO20064676 L NO 20064676L
Authority
NO
Norway
Prior art keywords
dimethylsuccinyl
betulinic acid
dsb
pharmaceutical salts
salts
Prior art date
Application number
NO20064676A
Other languages
Norwegian (no)
Inventor
Martin Dale Power
David Eugene Martin
Original Assignee
Panacos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacos Pharmaceuticals Inc filed Critical Panacos Pharmaceuticals Inc
Publication of NO20064676L publication Critical patent/NO20064676L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives salter av 3-O-(3',3'-dimetylsuccinyl) betulinsyre (DSB). Spesielt beskrives fremstilling, farmasøytisk evaluering og in vivo biotilgjengelighetsevaluering av N-metyl-D-glucamin og alkaliesaltformer av DSB. Videre beskrives farmasøytiske preparater inkludert disse saltformer for anvendelse i metoder for behandling av HIV og relaterte sykdommer. Det tilveiebringes også metoder for å fremstille saltene av DSB og også de farmasøytiske preparater.Salts of 3-O- (3 ', 3'-dimethylsuccinyl) betulinic acid (DSB) are described. Specifically, the preparation, pharmaceutical evaluation and in vivo bioavailability evaluation of N-methyl-D-glucamine and alkaline salt forms of DSB are described. Further, pharmaceutical compositions including these salt forms are disclosed for use in methods of treating HIV and related diseases. Methods are also provided for preparing the salts of DSB and also the pharmaceutical preparations.

NO20064676A 2004-03-17 2006-10-16 Pharmaceutical salts of 3-O- (3'3'-dimethylsuccinyl) betulinic acid NO20064676L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55355404P 2004-03-17 2004-03-17
US58467404P 2004-07-02 2004-07-02
PCT/US2005/008935 WO2005090380A1 (en) 2004-03-17 2005-03-17 Pharmaceuticals salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid

Publications (1)

Publication Number Publication Date
NO20064676L true NO20064676L (en) 2006-12-01

Family

ID=34993638

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064676A NO20064676L (en) 2004-03-17 2006-10-16 Pharmaceutical salts of 3-O- (3'3'-dimethylsuccinyl) betulinic acid

Country Status (11)

Country Link
US (2) US20050239748A1 (en)
EP (1) EP1730163A4 (en)
JP (1) JP2007529544A (en)
AU (1) AU2005224260A1 (en)
BR (1) BRPI0508854A (en)
CA (1) CA2560266A1 (en)
IL (1) IL178128A0 (en)
MX (1) MXPA06010592A (en)
NO (1) NO20064676L (en)
RU (1) RU2387665C2 (en)
WO (1) WO2005090380A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2383534T3 (en) * 2005-04-12 2012-06-22 Myrexis, Inc. 3-O- (3 ', 3'-dimethylsuccinyl) betulinic acid di-N-methyl-D-glucamine polymorphs
BRPI0619936A2 (en) * 2005-12-16 2011-10-25 Panacos Pharmaceuticals Inc preparation of pharmaceutical salts of 3-o- (3 ', 3'-dimethylsuccinyl) betulinic acid
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
CZ300722B6 (en) * 2006-09-27 2009-07-22 Univerzita Karlova v Praze, Prírodovedecká fakulta Process for preparing inclusion complex of pentacyclic and tetracyclic terpenoids, process for preparing pharmaceutical composition containing this inclusion complex, inclusion complex of pentacyclic or tetracyclic terpenoid and pharmaceutical compos
TW200837074A (en) 2006-11-03 2008-09-16 Panacos Pharmaceuticals Inc Extended triterpene derivatives
WO2008091532A1 (en) * 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
WO2012106190A1 (en) 2011-01-31 2012-08-09 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
JP2009120516A (en) * 2007-11-13 2009-06-04 Tokyo Medical Univ Antiviral agent
US8802727B2 (en) * 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
EA026140B1 (en) 2010-06-04 2017-03-31 Бристол-Майерс Сквибб Компани C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors
JP5752789B2 (en) * 2010-06-04 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Modified C-3 betulinic acid derivatives as HIV maturation inhibitors
US20140221328A1 (en) * 2011-01-10 2014-08-07 Bandi Parthasaradhi Reddy Pharmaceutically acceptable salts of novel betulinic acid derivatives
WO2012106188A1 (en) 2011-01-31 2012-08-09 Bristol-Myers Squibb Company C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors
RU2489147C2 (en) * 2011-08-31 2013-08-10 Людмила Петровна Лазурина Local pharmaceutical antibacterial composition of active biometallic complexes
ES2611727T3 (en) 2011-09-21 2017-05-10 VIIV Healthcare UK (No.5) Limited Novel betulinic acid derivatives with antiviral activity
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
CN105121454A (en) 2013-02-06 2015-12-02 百时美施贵宝公司 C-19 modified triterpenoids with HIV maturation inhibitory activity
EP2958930A1 (en) 2013-02-25 2015-12-30 Bristol-Myers Squibb Company C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
KR102411082B1 (en) 2014-04-11 2022-06-17 비브 헬스케어 유케이 (넘버4) 리미티드 Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
WO2016077561A1 (en) 2014-11-14 2016-05-19 Bristol-Myers Squibb Company Oxolupene derivatives
BR112017009852A2 (en) 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd compound, composition, and uses of a compound
MA40886B1 (en) 2015-02-09 2020-03-31 Hetero Research Foundation Novel c-3 triterpenone with c-28 reverse amide derivatives as hiv inhibitors
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
AR107512A1 (en) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD TRITERPENOIDS MODIFIED IN C-3 AND C-17 AS HIV-1 INHIBITORS
CN107625967B (en) 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 A kind of pharmaceutical composition for Tecoviride injection and preparation method thereof
CN107638571B (en) 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 A kind of oral pharmaceutical composition of Tecoviride and preparation method thereof
CA3075023A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Method and improved neuroprotective composition for treating neurological conditions
IL285232B (en) 2017-09-14 2022-07-01 Phoenix Biotechnology Inc Preparations containing oleandrin for the treatment of viral infection
EP3796900A4 (en) 2018-06-29 2022-03-30 DFH Therapeutics TRITERPEN AMINE DERIVATIVES
SG11202105728YA (en) 2020-03-31 2021-11-29 Phoenix Biotechnology Inc Method and compositions for treating coronavirus infection
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839344A (en) * 1973-03-28 1974-10-01 Schering Corp N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid
US4205073A (en) * 1975-04-30 1980-05-27 Schering Corporation Anti-diarrheal anilino nicotinic acids and method of using same
US4377583A (en) * 1981-08-21 1983-03-22 Mead Johnson & Company N-Methyl-D-glucamine salt of with 3,4-dihydro-5-methyl-6-(2-methylpropyl)-4-oxothieno[2,3-d]pyrimidine-2-carboxylic acid
JPS60163897A (en) * 1984-02-06 1985-08-26 Tokyo Tanabe Co Ltd Ursodeoxycholic acid meglumine salt and its injection
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
EP0538011B1 (en) * 1991-10-16 1997-07-30 Schering Corporation Lipophilic oligosaccharide antibiotic salt compositions
FR2683531B1 (en) * 1991-11-13 1993-12-31 Rhone Poulenc Rorer Sa NEW LUPANE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5679828A (en) * 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
GB9613455D0 (en) * 1996-06-27 1996-08-28 Aston Molecules Ltd Analogues or derivatives of quercetin
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
US6043245A (en) * 1997-09-25 2000-03-28 Schering Corporation Tetrahydrofuran antifungal phosphate
US6670345B1 (en) * 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
ATE348839T1 (en) * 1998-03-02 2007-01-15 Univ North Carolina ACYLATED BETULIN AND DIHYDROBETULIN DERIVATIVES, THEIR PREPARATION AND USE
WO1999067284A2 (en) * 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6147077A (en) * 1999-04-29 2000-11-14 Sepracor Inc. 2R,4S-hydroxyitraconazole isomers
US6579828B1 (en) * 1999-10-15 2003-06-17 Nippon Paper Industries Co. Ltd Multi chromatic thermally sensitive recording medium
US7276510B2 (en) * 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
US7365221B2 (en) * 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
JP2006520756A (en) * 2003-01-29 2006-09-14 パナコス ファーマシューティカルズ インコーポレーティッド Inhibition of HIV-1 replication by disruption of viral capsid spacer peptide 1 protein processing
US20050148561A1 (en) * 2003-09-26 2005-07-07 Panacos Pharmaceuticals, Inc. Novel triterpene derivatives, preparation thereof and use thereof
RU2243233C1 (en) * 2003-12-24 2004-12-27 Московская государственная академия тонкой химической технологии им. М.В. Ломоносова Derivatives of betulin as complement inhibitors

Also Published As

Publication number Publication date
AU2005224260A1 (en) 2005-09-29
US20120214775A1 (en) 2012-08-23
BRPI0508854A (en) 2007-08-28
EP1730163A1 (en) 2006-12-13
RU2387665C2 (en) 2010-04-27
WO2005090380A1 (en) 2005-09-29
EP1730163A4 (en) 2009-12-30
CA2560266A1 (en) 2005-09-29
JP2007529544A (en) 2007-10-25
RU2006136409A (en) 2008-04-27
US20050239748A1 (en) 2005-10-27
IL178128A0 (en) 2006-12-31
MXPA06010592A (en) 2007-06-12

Similar Documents

Publication Publication Date Title
NO20064676L (en) Pharmaceutical salts of 3-O- (3'3'-dimethylsuccinyl) betulinic acid
MX2009001711A (en) Sustained-release formulations of topiramate.
TNSN07290A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
NO20021701L (en) Process for the preparation of a conjugate of polyglutamate and a therapeutic agent
TR200401029T4 (en) Acylphenyl-urea derivatives, manufacturing methods and their use as pharmaceuticals
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
TR200302242T2 (en) Pyrolopyrimidines as protein kinase inhibitors
PL1687305T3 (en) 1h-imidazoquinoline derivatives as protein kinase inhibitors
BRPI0513959A (en) antibodies directed against beta-amyloid peptide, their pharmaceutical compositions, kit and methods of manufacture thereof
BRPI0916356A2 (en)
BR0114799A (en) Cyanophenoxy carboxylic acid compounds and compositions for releasing active agents
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
NO20090598L (en) 6,9-disubstituted purine derivatives and their use in the treatment of skin
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
ATE470443T1 (en) INDOL-1-YL ACID DERIVATIVES
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
TW200745155A (en) Preparation of pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl)betulinic acid
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
IL186058A0 (en) Polymorphs of 3-0-(3',3' -dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine salt
MX2007004861A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases.
UA83888C2 (en) Pharmaceutical composition of vinflunine for parenteral administration, preparation method thereof and use of same
WO2008074960A3 (en) New conjugates for therapeutic purposes and/or as diagnosis and/or imaging agents and method for preparing the same
YU19302A (en) 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application